Blog

John Lewis wins a place in the Falling Walls Venture competition in Berlin!

Falling Walls Venture – Berlin 2018

Congratulations to John Lewis and Nanostics for winning an entry into the highly competitive and prestigious Falling Walls Venture Conference in Berlin, November 8-9, 2018!

Five presenters pitched their healthcare-related ideas and innovations to a panel of tech and business-savvy judges and a large audience on Aug 29, 2018, at the University of Alberta in a high-stakes “TEDTalk” meets “Dragon’s Den” style. The competition was tough but John Lewis edged out the fellow contenders to win a chance to pitch a 5-minute talk on Nanostics’ high-accuracy prostate cancer diagnostic reflex test: ClarityDX Prostate.

John talked with Mark Connolly from the CBC Edmonton Morning show on September 4 about the Falling Walls competition and what he is preparing for this November.

Good luck to John Lewis at the Falling Walls Finale in Berlin!

John Lewis wins an entry to Falling Walls Berlin!

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

goes to...APCaRI member Russ Greiner Posted on Jun 15 21 at 7:51pm
Participation Milestone! Posted on May 29 21 at 6:12pm
Raja Singh Posted on Apr 30 21 at 12:24pm

New platform for prostate cancer diagnosis to be presented at ISEV 2017

The Lewis Research Group will present exciting results about new blood tests for prostate cancer during 3 talks at the upcoming 2017 International Society of Extracellular Vesicles (ISEV) annual meeting in Toronto (May 18-21). ISEV is a global society of researchers studying exosomes and microvesicles, which are the exciting new focus of cancer therapy and diagnosis.

Dr. Desmond Pink will speak about “Microflow cytometry: The Apogee A50 is a sensitive standard tool for extracellular vesicle analyses in liquid biopsies”, Robert Paproski’s presentation is entitled “Using machine learning of extracellular vesicle flow cytometry to build predictive fingerprints for prostate cancer diagnosis”, and Dr. John Lewis will speak about “An extracellular vesicle blood fingerprint distinguishes between patients with indolent and aggressive prostate cancer at diagnosis”.

The team is looking forward to sharing these key advances that were made possible through the APCaRI prospective cohort.

- John Lewis